Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2020
Real world evidence to support payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders
3 September 2020 - There are divergent views on the potential of real world data to inform decisions made by regulators, ...
Posted by Michael Wonder on 15 Jul 2020
The impact of managed entry agreements on pharmaceutical prices
6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...
Posted by Michael Wonder on 17 Jun 2020
Disagreement on cancer drug decisions in Europe
15 June 2020 - Despite the efforts of the European Union to promote voluntary cooperation among Health Technology Assessment agencies, different ...
Posted by Michael Wonder on 16 Mar 2020
A systematic review of economic evaluations of advanced therapy medicinal products
10 March 2020 - Advanced therapy medicinal products represent a new category of medicinal products with a potential for transformative improvements ...
Posted by Michael Wonder on 10 Mar 2020
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
10 March 2020 - For at least two decades, health technology assessment has been considered worldwide the most comprehensive and suitable ...
Posted by Michael Wonder on 19 Jan 2020
Closing the cycle of innovation in health care in Europe
17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 28 Sep 2019
AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available
27 September 2019 - Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene ...
Posted by Michael Wonder on 21 May 2019
The global battle over high drug prices
21 May 2019 - Western countries, as well as poor ones, are demanding transparency in the cost of drugs. ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 02 Apr 2019
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcarehe
1 April 2019 - Advanced therapy medicinal products are beginning to reach European markets, and questions are being asked about their ...
Posted by Michael Wonder on 28 Mar 2019
Take over pharma to create new medicines, says top adviser
27 March 2019 - Part of the drugs industry should be taken over to make new antibiotics, an influential economist ...
Posted by Michael Wonder on 14 Mar 2019
An EU wide approach to HTA: an irrelevant development or an opportunity not to be missed?
14 March 2019 - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness ...
Posted by Michael Wonder on 23 Feb 2019
Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model in a pharmaceutical company
21 February 2019 - Evidence requirements and assessment methods access differ between health technology assessment agencies. ...
Posted by Michael Wonder on 18 Feb 2019
Brexit: will Britons living in the EU still get health care?
18 February 2019 - If the UK leaves the EU without a deal, reciprocal health care arrangements will not automatically ...